(Q37315451)

English

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia

scientific article published on 21 September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia (English)

1 reference

Europe PubMed Central

19 August 2017

0 references

chronic schizophrenia

1 reference

based on heuristic

inferred from title

Robert A. Rosenheck

3

object named as

Robert A Rosenheck

1 reference

Europe PubMed Central

19 August 2017

Jeffrey Lieberman

8

object named as

Jeffrey A Lieberman

1 reference

Europe PubMed Central

19 August 2017

author name string

Donald E Addington

1

1 reference

Europe PubMed Central

19 August 2017

Somaia Mohamed

2

1 reference

Europe PubMed Central

19 August 2017

Sonia M Davis

4

1 reference

Europe PubMed Central

19 August 2017

Thomas Scott Stroup

5

1 reference

Europe PubMed Central

19 August 2017

Joseph P McEvoy

6

1 reference

Europe PubMed Central

19 August 2017

Marvin S Swartz

7

1 reference

Europe PubMed Central

19 August 2017

publication date

21 September 2010

1 reference

Europe PubMed Central

19 August 2017

The Journal of Clinical Psychiatry

1 reference

Europe PubMed Central

19 August 2017

72

1 reference

Europe PubMed Central

19 August 2017

75-80

1 reference

Europe PubMed Central

19 August 2017

1

1 reference

Europe PubMed Central

19 August 2017

Atypical antipsychotics for people with both schizophrenia and depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

The mesolimbic dopamine reward circuit in depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Schizophrenia and suicide: systematic review of risk factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Schizophrenia and deliberate self-harm: a systematic review of risk factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Practice guideline for the treatment of patients with schizophrenia, second edition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

Treatment of schizoaffective disorder and schizophrenia with mood symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

6 September 2017

N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

14 September 2017

A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

28 September 2017

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

28 September 2017

Depressive symptoms in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

26 June 2018

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

26 June 2018

Specificity of the Calgary Depression Scale for schizophrenics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

26 June 2018

Importance of Psychiatric Diagnosis in Prediction of Clinical Drug Effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

26 June 2018

Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5052810

2 September 2018

Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of four scales measuring depression in schizophrenic inpatients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing depression in schizophrenia: the Calgary Depression Scale

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depression in schizophrenia: a comparison of three measures

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency and differential diagnosis of depressive syndromes in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reliability and validity of a depression rating scale for schizophrenics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20868641

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4088/JCP.09M05258GRE

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37315451&oldid=2071484970"